Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 2Sarcoma 1Myeloid 1Lymphoid 1Head & Neck 1CNS 1Breast 1

Conditions

Squamous Cell Carcinoma of Head and Neck 169Head and Neck Neoplasms 151Carcinoma, Squamous Cell 33Neoplasm Metastasis 18Laryngeal Neoplasms 17Colorectal Neoplasms 17Tongue Neoplasms 16Neoplasms 16Mouth Neoplasms 16Recurrence 14Oropharyngeal Neoplasms 14Carcinoma, Non-Small-Cell Lung 14Salivary Gland Neoplasms 12Hypopharyngeal Neoplasms 11Carcinoma 11Laryngeal Diseases 10Breast Neoplasms 10Nasopharyngeal Carcinoma 9Pancreatic Neoplasms 6Neoplasms, Squamous Cell 6Sarcoma 5Pharyngeal Neoplasms 5Parkinson Disease 4, Autosomal Dominant Lewy Body 5Colonic Neoplasms 5Carcinoma, Renal Cell 5Stomach Neoplasms 4Rectal Neoplasms 4Ovarian Neoplasms 4Melanoma 4Lymphoid Interstitial Pneumonia 4

Interventions

temsirolimus 1pembrolizumab 1niraparib 1atezolizumab 1Valproic Acid 1Tissue Banks 1Sirolimus 1Immunoglobulin G 1GSK-3326595 1Etoposide 1Disulfides 1Cyclophosphamide 1Cetuximab 1Blood Specimen Collection 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Urologic Neoplasms × Cetuximab × Head & Neck × Clear all
NCT01552434 2026-05-15

Bevacizumab and Temsirolimus Alone or in Combination With Valproic Acid or Cetuximab in Treating Patients With Advanced or Metastatic Malignancy or Other Benign Disease

M.D. Anderson Cancer Center

Phase 1 Terminated
154 enrolled
BreastCNSGenitourinaryHead & NeckLymphoidMyeloidSarcoma

Breast Neoplasms, Carcinoma, Transitional Cell, Endocrine Gland Neoplasms, Castleman Disease, Mouth Neoplasms, Neoplasm Metastasis, Neoplasms, Pharyngeal Neoplasms, Recurrence, Sarcoma, Soft Tissue Neoplasms, Thyroid Neoplasms, Urologic Neoplasms, Neurofibromatosis 2, Lymphangioleiomyomatosis, Neoplasms, Mesothelial, Erdheim-Chester Disease

Data powered by HemOnc (CC BY 4.0) Colophon âš¡